Dr. David C. U'Prichard currently serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries from his base in Philadelphia, US, and as a Venture Partner at Red Abbey Venture Partners (Baltimore).

During 2003 - 2006, he was a Venture Partner for Apax Partners Ltd. (London) and Care Capital LLC (Princeton). Dr. U'Prichard is currently raising a new biotechnology venture fund, Druid BioVentures.

From 1999 to 2003 he was CEO of 3-Dimensional Pharmaceuticals, Inc., Yardley PA. During that time he took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson. In March 2003, 3DP become a part of Johnson & Johnson Pharmaceutical R&D.

From 1997 to 1999, Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U'Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia® and Iressa®.

Previously, Dr. U'Prichard was instrumental in the launch of Nova Pharmaceuticals, Baltimore MD in 1983, following an academic career as tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School (1978-83), and his postdoctoral fellowship at Johns Hopkins University (1975-78). Dr. U'Prichard received his Ph.D. in Pharmacology from the University of Kansas, and his B.S. in Pharmacology with first-class honors from the University of Glasgow, Scotland. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Pennsylvania and is an Honorary Professor at the University of Glasgow.

He is also an author of more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, co-editor of Epinephrine in the Central Nervous System and has served as a member of various editorial boards.

Dr. U'Prichard is Chairman of the Board of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC, Berkeley Heights, NJ) and Oxagen Ltd (Oxford, UK) and serves on the Board of Directors of Life Technologies Corp (NASDAQ: LIFE, Carlsbad, CA), Silence Therapeutics PLC (AIM:SLN, London, UK), Naurex, Inc. (Chicago, IL), Angstrom Pharmaceuticals (San Diego, CA), and Ocimum Biosolutions (Gaithersburg, MD and Hyderabad, India). Dr. U'Prichard was Chairman of the Pennsylvania Biotechnology Association 2004-2005 and has served on the boards of BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and the Bioethics Institute of the University of Pennsylvania.

Dr. U'Prichard is a consultant for Booz & Co., and is a Trustee of the International House of Philadelphia and The Wilma Theater, also in Philadelphia.